

Autoantibodies (tTG-IgA/-IgG, GLI-IgA/-IgG, PCA, IFA)

Optimisation of the Testing Method

Mainz, 8th June 2025

Dear colleagues,
dear members of the medical practice team,

we would like to inform you that, effective as of **15 June 2026**, we will be implementing a change in methodology for the determination of the following autoantibodies:

■ Coeliac Disease Diagnostics:

- Anti-transglutaminase antibodies (tTG-IgA and tTG-IgG)
- Anti-deamidated gliadin peptide antibodies (GLI-IgA and GLI-IgG)

■ Diagnostics of Chronic Atrophic Gastritis:

- Parietal cell antibodies (PCA)
- Intrinsic factor antibodies (IFA)

As part of the transition from the previous semi-quantitative or qualitative assays to a quantitative method, the **reference ranges** for all of the above parameters will be **standardised** as follows:

- Negative: < 7 U/ml
- Borderline elevated: 7-10 U/ml
- Positive: > 10 U/ml

Important note: Due to the change in the testing procedure, the new quantitative results are not directly comparable with previous findings.

Background:

The introduction of the new method enables a more objective assessment of antibody concentrations, which is of particular importance for patient monitoring and the evaluation of therapeutic interventions.

Do you have any questions?

Your designated scientific sales representative, as well as our customer service team, are available via email at info@ganzimmun.de or by phone on **+49 6131 7205-0**, Monday to Friday between 8 a.m. and 7 p.m.

Yours sincerely,



Dr. med. Patrik Zickgraf